Nutcracker Therapeutics Launches New CRDMO Services for RNA Drug Developers

• Nutcracker Therapeutics launches new contract research, development, and manufacturing organization (CRDMO) capabilities to support RNA drug developers, focusing on scalable, personalized RNA medicines.

• The company’s Nutcracker Manufacturing Unit (NMU), a biochip-based system, enables efficient, on-demand production of personalized RNA therapies, including cancer vaccines, with rapid turnaround times.

Nutcracker Therapeutics, a biotechnology company known for its proprietary RNA technology platform, has announced new contract research, development, and manufacturing organization (CRDMO) capabilities. The company’s expansion aims to provide scalable, flexible solutions to support RNA drug developers from early discovery to large-scale commercial production.

The new capabilities leverage the Nutcracker Manufacturing Unit (NMU), a cutting-edge, biochip-based system designed to support RNA drug development. Located in Emeryville, California, the company’s 8,000-square-foot, cGMP-compliant facility can manufacture personalized cancer vaccines (PCVs) for up to 2,000 patients annually, with a rapid three-week turnaround time. The facility uses single-use, customizable biochips that ensure the flexible, scalable production of personalized RNA treatments, such as cancer vaccines.

“Our ambition is to contribute to the proliferation of RNA medicines with our advanced technologies for the sake of patients in need,” said Igor Khandros, CEO of Nutcracker Therapeutics. The company believes that the future of RNA therapies will be increasingly personalised, with an emphasis on flexible, on-demand production to meet the unique needs of individual patients.

Nutcracker’s CRDMO services incorporate its advanced manufacturing system and design capabilities, which aim to accelerate RNA therapies’ speed to clinic while maintaining high quality and low production costs. The NMU offers efficient control over the production process, ensuring high yield, purity, and reproducibility for research, clinical, and commercial-grade materials.

This new platform builds on the company’s previous success with RNA production and has received favourable feedback from the U.S. Food and Drug Administration (FDA). Nutcracker’s goal is to support a broad range of RNA treatments, including cancer vaccines and other personalized RNA-based medicines, contributing to the growing RNA therapeutic landscape.